Mayo Clinic at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Mayo Clinic takes part in 5 sessions at ESMO 2026 in Madrid. Its program centres on radioligand therapy and theranostics for neuroendocrine tumours, along with brain and other central nervous system tumours. It presents results for a lead-212 radioligand in advanced neuroendocrine tumours expressing somatostatin receptor 2, and looks at the patient experience of radiopharmaceutical therapy.
| Organization | ESMO 2026 Attendance |
|---|---|
Mayo Clinic Rochester, MN | |
Nonprofit academic medical centre in Rochester, Minnesota, with an NCI-designated comprehensive cancer centre. | Chair Fri Oct 23 13:30–15:00 Rapid oral: CNS tumours Sarcoma, CNS, head & neck and rare cancers Abstract Fri Oct 23 13:45–13:57 Invited Discussant 695RO, 696RO and 697RO Sarcoma, CNS, head & neck and rare cancers Abstract Fri Oct 23 16:25–16:30 Chair Sat Oct 24 10:15–11:45 Theranostics: A magic bullet story from theory to clinics Sarcoma, CNS, head & neck and rare cancers Chair Sun Oct 25 14:45–16:15 Radioligand therapy: A game-changer in the treatment sequence of advanced neuroendocrine tumors Sarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 15:45–16:05 Looking ahead: Next frontiers of radioligands in neuroendocrine neoplasms Sarcoma, CNS, head & neck and rare cancers Satellite Mon Oct 26 18:45–19:15 Satellite Mon Oct 26 19:15–19:25 Satellite Mon Oct 26 19:25–19:40 |
Instantly find 20 buyers from Mayo Clinic
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction